KR20210108902A - Pharmaceutical composition comprising deoxycholic acid - Google Patents
Pharmaceutical composition comprising deoxycholic acid Download PDFInfo
- Publication number
- KR20210108902A KR20210108902A KR1020210025503A KR20210025503A KR20210108902A KR 20210108902 A KR20210108902 A KR 20210108902A KR 1020210025503 A KR1020210025503 A KR 1020210025503A KR 20210025503 A KR20210025503 A KR 20210025503A KR 20210108902 A KR20210108902 A KR 20210108902A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutical composition
- acid
- sodium
- deoxycholic acid
- dca
- Prior art date
Links
- 229960003964 deoxycholic acid Drugs 0.000 title claims abstract description 70
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 title claims abstract description 70
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 title claims abstract description 70
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 51
- 239000000654 additive Substances 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 230000000996 additive effect Effects 0.000 claims abstract description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 66
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 54
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 33
- 229920005862 polyol Polymers 0.000 claims description 30
- 150000003077 polyols Chemical class 0.000 claims description 30
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 22
- 229930006000 Sucrose Natural products 0.000 claims description 22
- 239000005720 sucrose Substances 0.000 claims description 22
- 239000001509 sodium citrate Substances 0.000 claims description 20
- 239000006174 pH buffer Substances 0.000 claims description 19
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 18
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 17
- 235000011083 sodium citrates Nutrition 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 12
- 229930195725 Mannitol Natural products 0.000 claims description 12
- 239000000594 mannitol Substances 0.000 claims description 12
- 235000010355 mannitol Nutrition 0.000 claims description 12
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 11
- 239000001488 sodium phosphate Substances 0.000 claims description 11
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 10
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 10
- 235000019800 disodium phosphate Nutrition 0.000 claims description 10
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 10
- 239000003002 pH adjusting agent Substances 0.000 claims description 9
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 9
- 235000011008 sodium phosphates Nutrition 0.000 claims description 9
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 9
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 claims description 8
- 208000008589 Obesity Diseases 0.000 claims description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 8
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 8
- 229940024606 amino acid Drugs 0.000 claims description 8
- 235000001014 amino acid Nutrition 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 8
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 8
- 239000002736 nonionic surfactant Substances 0.000 claims description 8
- 235000020824 obesity Nutrition 0.000 claims description 8
- 238000007911 parenteral administration Methods 0.000 claims description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- 235000015165 citric acid Nutrition 0.000 claims description 5
- 229930182817 methionine Natural products 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- 239000001361 adipic acid Substances 0.000 claims description 4
- 235000011037 adipic acid Nutrition 0.000 claims description 4
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 4
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 4
- 229960004926 chlorobutanol Drugs 0.000 claims description 4
- 229960002242 chlorocresol Drugs 0.000 claims description 4
- 229930003836 cresol Natural products 0.000 claims description 4
- 229940013361 cresol Drugs 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 229960003742 phenol Drugs 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 235000008729 phenylalanine Nutrition 0.000 claims description 4
- 229960005190 phenylalanine Drugs 0.000 claims description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 235000010216 calcium carbonate Nutrition 0.000 claims description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 3
- 239000000920 calcium hydroxide Substances 0.000 claims description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 3
- 235000011116 calcium hydroxide Nutrition 0.000 claims description 3
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 3
- 239000001527 calcium lactate Substances 0.000 claims description 3
- 235000011086 calcium lactate Nutrition 0.000 claims description 3
- 229960002401 calcium lactate Drugs 0.000 claims description 3
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 229940073490 sodium glutamate Drugs 0.000 claims description 3
- 239000001540 sodium lactate Substances 0.000 claims description 3
- 235000011088 sodium lactate Nutrition 0.000 claims description 3
- 229940005581 sodium lactate Drugs 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 3
- 229940038773 trisodium citrate Drugs 0.000 claims description 3
- 235000019263 trisodium citrate Nutrition 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 239000006035 Tryptophane Substances 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 229960002433 cysteine Drugs 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 235000004554 glutamine Nutrition 0.000 claims description 2
- 229960002743 glutamine Drugs 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 235000011007 phosphoric acid Nutrition 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims description 2
- 229960001153 serine Drugs 0.000 claims description 2
- 235000004400 serine Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 235000008521 threonine Nutrition 0.000 claims description 2
- 229960002898 threonine Drugs 0.000 claims description 2
- 229960004799 tryptophan Drugs 0.000 claims description 2
- 235000017103 tryptophane Nutrition 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 239000013011 aqueous formulation Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 description 67
- 239000000203 mixture Substances 0.000 description 66
- 238000001556 precipitation Methods 0.000 description 51
- 238000009472 formulation Methods 0.000 description 43
- 230000000052 comparative effect Effects 0.000 description 33
- 238000003860 storage Methods 0.000 description 25
- 238000001879 gelation Methods 0.000 description 23
- 239000000243 solution Substances 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000008215 water for injection Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 239000013049 sediment Substances 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 230000003139 buffering effect Effects 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 210000002683 foot Anatomy 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000004130 lipolysis Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 6
- 229920001993 poloxamer 188 Polymers 0.000 description 6
- 229940044519 poloxamer 188 Drugs 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 238000004062 sedimentation Methods 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000010792 warming Methods 0.000 description 6
- -1 alkali metal salt Chemical class 0.000 description 5
- 239000012669 liquid formulation Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000003204 osmotic effect Effects 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 206010006784 Burning sensation Diseases 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000000019 Sterol Esterase Human genes 0.000 description 2
- 108010055297 Sterol Esterase Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102100038968 WAP four-disulfide core domain protein 1 Human genes 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 235000010338 boric acid Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000002366 lipolytic effect Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- UYVVLXVBEQAATF-UHFFFAOYSA-N 4-(1,3,7,12-tetrahydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoic acid Chemical compound OC1CC2CC(O)CC(O)C2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 UYVVLXVBEQAATF-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960002645 boric acid Drugs 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001844 chromium Chemical class 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 데옥시콜릭산을 포함하는 약제학적 조성물에 관한 것이다. The present invention relates to a pharmaceutical composition comprising deoxycholic acid.
지방분해(lipolysis)란 지방 세포에 포함되어 있는 중성 지방이 분해되는 것으로서, 호르몬 감수성 리파아제(Hormone sensitive lipase, HSL)의 작용에 의해서 중성 지방이 자유 지방산(free fatty acid, FFA)과 글리세롤(glycerol)로 분해되는 과정을 의미하는 것이며, 호르몬이나 자율신경에 의해서 조절된다. 최근에는 운동 또는 식이요법보다 손쉬운 체중 감량 또는 몸매관리를 위한 방법 중 하나로 이러한 지방분해를 이용한 지방분해주사가 인기를 얻고 있다. Lipolysis is the breakdown of triglycerides contained in adipocytes, and by the action of hormone sensitive lipase (HSL), triglycerides are converted into free fatty acids (FFA) and glycerol (glycerol). It means the process of decomposition, and is regulated by hormones or autonomic nerves. Recently, as one of the methods for easier weight loss or body management than exercise or diet, lipolysis injection using such lipolysis is gaining popularity.
데옥시콜린산(deoxycholic acid, DCA)의 지방분해 용도는 이미 알려져 있다. 최근에 발표된 문헌들은 데옥시콜린산의 수용성 용액이 생체내 지방성 축적물 내로 주입될 때 지방을 제거하는 성질을 가지는 것으로 보고하고 있다(국제특허출원 WO 2005/117900 및 WO2005/112942, 미국특허출원 US2005/0261258; US2005/0267080; US2006/127468; 및 US2006/0154906 등). The lipolytic use of deoxycholic acid (DCA) is already known. Recently published documents report that an aqueous solution of deoxycholic acid has a property of removing fat when injected into a fatty deposit in vivo (International Patent Application WO 2005/117900 and WO 2005/112942, US Patent Application US2005/0261258; US2005/0267080; US2006/127468; and US2006/0154906, etc.).
또한, 데옥시콜린산(DCA)은 용해도(Solubility)가 높아, 제제시 용이하다는 장점이 있다. 그러나 데옥시콜린산(DCA)의 수용성 조성물은 이러한 장점에도 불구하고, 선택적으로 벤질 알코올을 포함하는 수용성 용액들에서 낮은 농도로 일정 기간 동안 보관 되는 경우 하얀색의 침전물을 형성하는 것으로 알려져 있으며, 놀랍게도 데옥시콜린산(DCA) 농도가 더 낮아질수록 침전의 속도가 더욱 빨라지는 것으로 밝혀진 바 있다. 이러한 침전은 데옥시콜린산(DCA)의 피하 주사들이 낮은 농도에서 역-지시 (counter-indicated)되어 발생하는 것으로 알려져 있으며, 시중에 유통되는 미용 주사제들의 평균적인 유효기간이 24개월 이상인 점을 감안할 때 침전물이 발생하면 사실상 안정성을 이유로 상용화가 불가하다.In addition, deoxycholic acid (DCA) has a high solubility (Solubility), it has the advantage of easy formulation. However, despite these advantages, the aqueous composition of deoxycholic acid (DCA) is known to form a white precipitate when stored for a period of time at a low concentration in aqueous solutions containing optionally benzyl alcohol. It has been found that the lower the concentration of oxycholic acid (DCA), the faster the rate of precipitation. This precipitation is known to occur because subcutaneous injections of deoxycholic acid (DCA) are counter-indicated at low concentrations, and considering that the average shelf life of cosmetic injections on the market is 24 months or more. When a precipitate occurs, it is practically impossible to commercialize due to stability reasons.
이를 해결하기 위한 한 가지 방법으로, 데옥시콜린산(DCA)의 농도를 훨씬 높게, 예를 들어, 5중량% 내지 약 16중량% 농도로 제조한 후, 의사의 사용 직전에 상기 용액을 희석하여 사용하는 방법이 있었다. 그러나 이 방법은 보관 안정성에는 효과적일 수 있으나, 일상적인(routine) 사용의 방법으로서 특히 많아야 약 0.2 mL의 무균의 주사 가능한 용액이 요구되는 경우라면 이상적이지 않다. 더구나, 현재의 임상적 치료방법은 치료 세션 당 50회까지의 주사를 포함하고 있어서 매 주사마다 일일이 희석하여 사용하기에는 불편함이 따른다. As one way to solve this, the concentration of deoxycholic acid (DCA) is prepared at a much higher concentration, for example, from 5% by weight to about 16% by weight, and then the solution is diluted immediately before use by a doctor. There was a way to use it. However, although this method can be effective for storage stability, it is not ideal for routine use, especially when a sterile injectable solution of at most about 0.2 mL is required. Moreover, the current clinical treatment method includes up to 50 injections per treatment session, so it is inconvenient to dilute each injection individually.
다른 해결하기 위한 방법으로, pH를 8.5까지 높인 범위로 조절하여 침전물이 발생되지 않는 시판 제품이 판매되고 있으나, 높은 pH로 인한 작열감, 염증과 같은 부작용이 보고된 바 있어, 보다 낮은 pH에서 침전 안정성을 만족하면서도 부작용이 감소된 제제의 개발이 필요한 실정이다. As another solution, a commercial product that does not cause sediment by adjusting the pH to 8.5 is sold, but side effects such as burning and inflammation due to high pH have been reported, so sedimentation stability at lower pH There is a need for the development of a formulation with reduced side effects while satisfying the requirements.
본 발명은 데옥시콜린산(DCA)을 함유하는 약제학적 조성물에 있어서, 종래의 데옥시콜린산(DCA)을 함유하는 약제학적 조성물에 비하여 낮은 pH에서도 침전물이 발생하지 않아 보관 안정성이 우수할 뿐 아니라, 투여부위에서 작열감, 염증 등의 부작용을 최소화할 수 있는 데옥시콜린산(DCA)을 함유하는 약제학적 조성물을 제공하고자 하는 것이다. In the pharmaceutical composition containing deoxycholic acid (DCA), the present invention has excellent storage stability because no precipitate is generated even at low pH compared to the conventional pharmaceutical composition containing deoxycholic acid (DCA). Rather, it is an object to provide a pharmaceutical composition containing deoxycholic acid (DCA) that can minimize side effects such as burning sensation and inflammation at the site of administration.
본 발명은 데옥시콜린산(Deoxycholic acid, DCA) 또는 그의 약제학적으로 허용되는 염을 포함하고, 약제학적으로 허용 가능한 첨가제를 포함하며, pH가 7.0 내지 8.0이고, 25℃에서 전기전도도가 5mS/cm 이하인 약제학적 조성물을 제공한다. The present invention includes deoxycholic acid (DCA) or a pharmaceutically acceptable salt thereof, includes a pharmaceutically acceptable additive, has a pH of 7.0 to 8.0, and has an electrical conductivity of 5 mS/ cm or less.
본 발명에 따른 데옥시콜린산(DCA)을 함유하는 약제학적 조성물은 보관 기간 동안 침전물이 발생하지 않고 우수한 보관 안정성을 나타낼 수 있다. 또한, 종래의 데옥시콜린산(DCA)을 함유하는 약제학적 조성물에 비하여 낮은 pH를 가짐에 따라 인체 내 pH와 유사해지고, 주사 부위 국소 pH의 회복이 빨라져 주사 통증을 현저히 완화할 수 있고, 투여 부위에서 작열감, 염증 등의 부작용이 발생하는 것을 최소화할 수 있다. 이에 따라, 본 발명의 데옥시콜린산(DCA)을 함유하는 약제학적 조성물은 지방분해(lipolysis), 비만 특히 국소 비만의 예방 및 치료에 유용하게 사용될 수 있다. The pharmaceutical composition containing deoxycholic acid (DCA) according to the present invention may exhibit excellent storage stability without the occurrence of sediment during storage. In addition, as it has a lower pH compared to the conventional pharmaceutical composition containing deoxycholic acid (DCA), it becomes similar to the pH in the human body, and the recovery of the local pH at the injection site is accelerated, so that the injection pain can be remarkably relieved, and administration It is possible to minimize the occurrence of side effects such as burning sensation and inflammation at the site. Accordingly, the pharmaceutical composition containing deoxycholic acid (DCA) of the present invention can be usefully used for the prevention and treatment of lipolysis, obesity, particularly local obesity.
도 1 및 도 2는 pH 완충능 비교 실험의 결과를 나타내는 그래프이다. 1 and 2 are graphs showing the results of the pH buffering capacity comparison experiment.
이하, 본 발명에 대한 이해를 돕기 위해 본 발명을 더욱 상세하게 설명한다. 이때, 본 명세서 및 청구범위에 사용된 용어나 단어는 통상적이거나 사전적인 의미로 한정해서 해석되어서는 아니 되며, 발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야만 한다. Hereinafter, the present invention will be described in more detail to help the understanding of the present invention. At this time, the terms or words used in the present specification and claims should not be construed as being limited to conventional or dictionary meanings, and the inventor appropriately defines the concept of the term in order to best describe his invention. Based on the principle that it can be done, it should be interpreted as meaning and concept consistent with the technical idea of the present invention.
본 발명은 데옥시콜린산(Deoxycholic acid, DCA) 또는 그의 약제학적으로 허용되는 염을 포함하고, 약제학적으로 허용 가능한 첨가제를 포함하며, pH가 7.0 내지 8.0이고, 25℃에서 전기전도도가 5mS/cm 이하인 약제학적 조성물을 제공한다.The present invention includes deoxycholic acid (DCA) or a pharmaceutically acceptable salt thereof, includes a pharmaceutically acceptable additive, has a pH of 7.0 to 8.0, and has an electrical conductivity of 5 mS/ cm or less.
상기 데옥시콜린산 또는 그의 약제학적으로 허용되는 염은 모두 공지 물질로서, 공지의 방법에 따라 제조할 수 있다. 예를 들어, 상기 데옥시콜린산 또는 이의 염은 동물 유래, 예를 들면 소의 담즙산(Bile acid)을 추출후 결정화(crystallization) 및 정제하여 고순도의 데옥시콜린산 또는 이의 염으로 제조할 수 있다. 또한, 상기 데옥시콜린산 또는 이의 염은 상업적으로 구입할 수 있다(예를 들어, Sigma-aldrich, PCA S.P.A 등으로부터 구입 가능). The deoxycholic acid or a pharmaceutically acceptable salt thereof are all known substances, and may be prepared according to a known method. For example, the deoxycholic acid or its salt can be prepared as high-purity deoxycholic acid or a salt thereof by crystallization and purification after extraction of bile acid from animals, for example, cattle. In addition, the deoxycholic acid or a salt thereof can be purchased commercially (eg, from Sigma-aldrich, PCA S.P.A, etc.).
본 발명의 상기 데옥시콜린산은 약제학적으로 허용 가능한 염의 형태일 수 있다. 데옥시콜린산은 (4R)-4-((3R,5R,10S,12S,13R,17R)-3,12-디하이드록시-10,13-디메틸헥사데카하이드로-1H-고리펜타[a]페난트렌-17-일)펜타노에이트이며, 상기 염은 약학적으로 허용 가능한 염으로서 통상의 금속염 형태, 예를 들어 리튬, 소듐, 또는 칼륨과 같은 알칼리 금속염; 칼슘 또는 마그네슘염과 같은 알카리 토금속염; 또는 크롬염을 포함하나, 이에 한정되지는 않는다.The deoxycholic acid of the present invention may be in the form of a pharmaceutically acceptable salt. Deoxycholic acid is (4R)-4-((3R,5R,10S,12S,13R,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclicpenta[a]phenane Tren-17-yl)pentanoate, wherein the salt is a pharmaceutically acceptable salt, in the form of a conventional metal salt, for example, an alkali metal salt such as lithium, sodium, or potassium; alkaline earth metal salts such as calcium or magnesium salts; or chromium salts.
본 발명에 따른 상기 데옥시콜린산(DCA)을 함유하는 약제학적 조성물은 상기 데옥시콜린산(DCA) 또는 그의 약제학적으로 허용되는 염을 1 내지 50mg/mL으로 포함할 수 있으며, 보다 바람직하게는 5 내지 30mg/mL, 더욱 바람직하게는 5 내지 20mg/mL, 더욱 더 바람직하게는 5 내지 15mg/mL 로 포함할 수 있다. 상기 범위 내로 데옥시콜린산(DCA) 또는 그의 약제학적으로 허용되는 염을 포함함으로써 지방 분해 효과를 나타내는 데옥시콜린산(DCA)을 적절한 양으로 용이하게 투여할 수 있다. The pharmaceutical composition containing deoxycholic acid (DCA) according to the present invention may include 1 to 50 mg/mL of deoxycholic acid (DCA) or a pharmaceutically acceptable salt thereof, more preferably is 5 to 30 mg/mL, more preferably 5 to 20 mg/mL, even more preferably 5 to 15 mg/mL. By including deoxycholic acid (DCA) or a pharmaceutically acceptable salt thereof within the above range, deoxycholic acid (DCA) exhibiting a lipolytic effect can be easily administered in an appropriate amount.
본 발명의 약제학적 조성물은 바람직하게는 비경구로 투여될 수 있으며, 더욱 바람직하게는 비경구로 국소 투여될 수 있다. 상기 국소 투여는 눈 밑, 턱 밑, 팔 밑, 엉덩이, 종아리, 등, 넓적다리, 발목, 복부 부위 등에 국소로 적용되는 것을 포함한다. 예를 들어, 본 발명의 약제학적 조성물은 비경구 투여용 제제(국소 투여 제제를 포함)로 제제화될 수 있으며, 상기 비경구 투여용 제제는 경피 투여용 제제, 피하 투여용 제제, 정맥내 투여용 제제, 근육내 투여용 제제 또는 복강내 투여용 제제일 수 있고, 보다 바람직하게는 피하 투여용 제제일 수 있다. 또한, 상기 비경구 투여용 제제는 단회 투여용 또는 수회 투여용 제제일 수 있다. 상기 수회 투여용 제제는 약 0.2 ml의 용적으로 7일 내지 1개월 간격으로 총 6회까지 시행 가능하며, 1일 최대 60회 이하 투여되기에 적합하도록 제조될 수 있다. 필요에 따라 상기 비경구 투여용 제제는 0.5 내지 2.0cm로 이격된 부위에 반복 투여될 수 있다.The pharmaceutical composition of the present invention may be preferably administered parenterally, and more preferably parenterally administered topically. The topical administration includes topical application under the eyes, under the chin, under the arms, buttocks, calves, back, thighs, ankles, abdomen, and the like. For example, the pharmaceutical composition of the present invention may be formulated as a preparation for parenteral administration (including a topical administration preparation), and the preparation for parenteral administration is a preparation for transdermal administration, a preparation for subcutaneous administration, and a preparation for intravenous administration. It may be a formulation, a formulation for intramuscular administration, or a formulation for intraperitoneal administration, and more preferably a formulation for subcutaneous administration. In addition, the formulation for parenteral administration may be a formulation for single administration or multiple administration. The formulation for multiple administration can be administered up to a total of 6 times at intervals of 7 days to 1 month in a volume of about 0.2 ml, and can be prepared to be administered up to 60 times a day or less. If necessary, the formulation for parenteral administration may be repeatedly administered to a site spaced apart by 0.5 to 2.0 cm.
상기 비경구 투여용 제제는 용액, 에멀젼, 현탁액, 동결건조 등의 형태를 포함하며, 바람직하게는 용액 또는 에멀젼의 형태를 포함한다. 상기 액상 제제는 앰플, 시린지 또는 바이알에 충전될 수 있고, 보다 바람직하게는 침전이나 겔화 발생을 줄이기 위해 시린지에 충전될 수 있다. 또한, 충전 전에 제균 여과기 등으로 무균 여과하거나, 가능한 경우 충전 후 사후 멸균하여 제제의 무균성을 확보할 수 있다.The formulation for parenteral administration includes solutions, emulsions, suspensions, freeze-drying, and the like, and preferably includes solutions or emulsions. The liquid formulation may be filled in ampoules, syringes or vials, and more preferably, may be filled in syringes to reduce the occurrence of precipitation or gelation. In addition, the sterility of the preparation can be secured by aseptic filtration with a sterilization filter or the like before filling, or post-sterilization after filling if possible.
상기 액상 제제의 형태의 비경구 투여용 제제는 약제학적으로 허용 가능한 첨가제 및/또는 담체를 사용하여 제제학 분야에서 통상적으로 사용되는 제제화 방법에 따라 제조될 수 있다. 따라서, 본 발명의 약제학적 조성물은 등장화제, 보존제(혹은 항균제), pH 조절제, 안정화제, 용해보조제, 용해도증강제, 계면활성제, 항산화제 및 무통화제로 이루어진 군으로부터 하나 이상 선택된 약제학적으로 허용 가능한 첨가제; 유기 용매 및 수성 용매로 이루어진 군으로부터 하나 이상 선택된 약학적으로 허용 가능한 담체를 포함할 수 있다. The liquid formulation for parenteral administration may be prepared according to a formulation method commonly used in the pharmaceutical field using pharmaceutically acceptable additives and/or carriers. Accordingly, the pharmaceutical composition of the present invention is a pharmaceutically acceptable one or more selected from the group consisting of isotonic agents, preservatives (or antibacterial agents), pH adjusters, stabilizers, solubilizers, solubility enhancers, surfactants, antioxidants and analgesics. additive; One or more pharmaceutically acceptable carriers selected from the group consisting of organic solvents and aqueous solvents may be included.
상기 pH 조절제는 주사용 제제에 통상적으로 사용되는 pH 조절제를 포함하며, 예를 들어 디에탄올아민, 아세트산, 메글루민, 시트르산나트륨, 수산화나트륨, 아디프산, 시트르산, 염산, 락트산, 황산, 타타르산, 인산 등을 포함하나, 이에 제한되는 것은 아니다. 본 발명의 조성물은 상기 pH 조절제를 0.1-5mg/mL으로 포함할 수 있으며, 바람직하게는 0.1-4mg/mL, 보다 바람직하게는 0.1-3mg/mL, 보다 더 바람직하게는 0.1-2mg/mL, 보다 더 바람직하게는 0.1-1.5mg/mL 의 농도로 포함할 수 있다. 본 발명의 약제학적 조성물은 pH 7.0 내지 pH 8.0의 범위, 예컨대 pH 7.3 내지 pH 8.0의 범위, 보다 구체적으로 pH 7.5 내지 8.0의 범위를 가질 수 있다. 상기 pH 범위를 갖는 약제학적 조성물은 국소 투여될 경우, 통증 및/또는 염증을 최소화할 수 있다. 예를 들어, 일반적인 건강한 사람의 신체는 위액과 소변을 제외하고는 pH 7.2 ~ 7.8을 유지하며, 이 중 혈액 등의 체액은 보통 pH 7.4 정도(약 pH 7.35-7.45의 범위)이다. 이러한, pH 값의 작은 변화에도 민감하게 반응할 수 있는데, 일례로 pH 8을 초과하는 조성물의 경우 체액의 pH 보다 너무 높은 pH를 가져 투여 부위에서 작열감과 같은 통증, 염증 반응 등의 부작용이 발생할 수 있다. 때문에, 체내에 투여되는 조성물의 경우 체액과 유사한 범위의 pH 값을 갖는 것이 바람직하다. 본 발명의 약제학적 조성물은 pH 7.0 내지 pH 8.0의 범위, 예컨대 pH 7.3 내지 pH 8.0의 범위, 보다 구체적으로 pH 7.5 내지 8.0의 범위를 가질 수 있고, 따라서 체내 투여 시 작열감과 같은 통증이나 염증 반응과 같은 부작용을 최소화할 수 있다.The pH adjusting agent includes a pH adjusting agent commonly used in injectable formulations, for example, diethanolamine, acetic acid, meglumine, sodium citrate, sodium hydroxide, adipic acid, citric acid, hydrochloric acid, lactic acid, sulfuric acid, tartar acid, phosphoric acid, and the like, but is not limited thereto. The composition of the present invention may contain the pH adjusting agent in an amount of 0.1-5 mg/mL, preferably 0.1-4 mg/mL, more preferably 0.1-3 mg/mL, even more preferably 0.1-2 mg/mL, More preferably, it may be included at a concentration of 0.1-1.5 mg/mL. The pharmaceutical composition of the present invention may have a range of pH 7.0 to pH 8.0, such as a range of pH 7.3 to pH 8.0, more specifically a range of pH 7.5 to 8.0. The pharmaceutical composition having the above pH range can minimize pain and/or inflammation when administered topically. For example, the body of a normal healthy person maintains a pH of 7.2 to 7.8 except for gastric juice and urine, of which body fluids such as blood usually have a pH of 7.4 (range of about pH 7.35-7.45). Such a small change in the pH value may also be sensitively reacted. For example, in the case of a composition exceeding pH 8, the pH of the body fluid is too high, so side effects such as pain and inflammatory reaction may occur at the administration site. have. Therefore, in the case of a composition administered into the body, it is preferable to have a pH value in a range similar to that of a body fluid. The pharmaceutical composition of the present invention may have a range of pH 7.0 to pH 8.0, for example, a range of pH 7.3 to pH 8.0, more specifically, a range of pH 7.5 to 8.0, and thus may have a pain or inflammatory reaction such as burning sensation upon administration in the body. The same side effects can be minimized.
본 발명에 따른 상기 데옥시콜린산(DCA)을 함유하는 약제학적 조성물은 25℃에서 전기전도도가 5mS/cm 이하이다. 보다 구체적으로는, 25℃에서 전기전도도가 0.1mS/cm 내지 5mS/cm, 더 구체적으로 0.1mS/cm 내지 4mS/cm, 보다 더 구체적으로 0.1mS/cm 내지 3mS/cm일 수 있다. The pharmaceutical composition containing deoxycholic acid (DCA) according to the present invention has an electrical conductivity of 5 mS/cm or less at 25°C. More specifically, the electrical conductivity at 25° C. may be 0.1 mS/cm to 5 mS/cm, more specifically 0.1 mS/cm to 4 mS/cm, and even more specifically 0.1 mS/cm to 3 mS/cm.
본 발명에 따른 상기 데옥시콜린산(DCA)을 함유하는 약제학적 조성물은 pH 완충제(buffer)를 실질적으로 포함하지 않을 수 있다. 이러한 본 발명에 따른 상기 데옥시콜린산(DCA)을 함유하는 약제학적 조성물은 이온성인 pH 완충제(buffer)를 실질적으로 사용하지 않으므로, 25℃에서 전기전도도를 낮출 수 있고, 5mS/cm 이하를 만족할 수 있다. 종래에는 일정한 범위의 pH을 유지하기 위하여 pH 완충제(buffer)를 사용하는 것이 일반적이었다. 일반적으로 상기 pH 완충제(buffer)로 사용되는 것은 예를 들어, 아디프산, 붕산, 탄산칼슘, 수산화칼슘, 젖산칼슘, 인산삼석회, 소듐 포스페이트, 시트르산, 말레산, 말산, 글루탐산나트륨, 아세트산나트륨, 탄산수소나트륨, 붕산, 시트르산삼나트륨, 소듐락테이트, 트리에탄올아민, 무수인산수소나트륨 등이 있으며, 대표적으로는 무수인산수소나트륨 및/또는 시트르산이 사용되었다. 그러나, 본 발명의 발명자는 pH 완충제(buffer)를 포함하지 않고도 pH 7.0 내지 8.0의 범위에서 일정한 범위로 pH가 유지되는 것을 확인하였다. 나아가, pH 완충제(buffer)를 포함하지 않음으로써 pH 7.0 내지 8.0의 범위에서도 겔화 및 침전이 발생하지 않아 보관 안정성이 현저히 우수해졌다. 또한, pH를 유지하기 위한 pH 완충제(buffer)를 사용하지 않음으로써 완충제에 의한 pH 완충 작용이 없기 때문에 더욱 빠르게 주사 부위의 국소 pH가 회복될 수 있고, 주사 통증이 현저히 완화될 수 있다.The pharmaceutical composition containing deoxycholic acid (DCA) according to the present invention may not include a pH buffer substantially. Since the pharmaceutical composition containing deoxycholic acid (DCA) according to the present invention does not substantially use an ionic pH buffer, it is possible to lower the electrical conductivity at 25° C., and to satisfy 5 mS/cm or less. can Conventionally, it is common to use a pH buffer (buffer) to maintain a pH in a certain range. Generally used as the pH buffer is, for example, adipic acid, boric acid, calcium carbonate, calcium hydroxide, calcium lactate, trilime phosphate, sodium phosphate, citric acid, maleic acid, malic acid, sodium glutamate, sodium acetate, There are sodium hydrogen carbonate, boric acid, trisodium citrate, sodium lactate, triethanolamine, anhydrous sodium hydrogen phosphate, and the like, and representative anhydrous sodium hydrogen phosphate and/or citric acid are used. However, the inventors of the present invention have confirmed that the pH is maintained in a constant range in the range of pH 7.0 to 8.0 without including a pH buffer (buffer). Furthermore, by not including a pH buffer (buffer), gelation and precipitation did not occur even in the range of pH 7.0 to 8.0, and storage stability was significantly improved. In addition, since there is no pH buffering action by the buffer by not using a pH buffer for maintaining the pH, the local pH of the injection site can be restored more quickly, and the injection pain can be remarkably relieved.
상기 본 발명의 조성물이 상기 pH 완충제(buffer)를 실질적으로 사용하지 않는다는 것은 본 발명의 조성물이 pH 완충제를 실질적으로 포함하지 않음으로써 25℃에서 전기전도도가 5mS/cm 이하를 만족한다는 의미이므로, 본 발명의 조성물이 25℃에서 전기전도도가 5mS/cm 이하의 값을 갖는다는 전제하에 본 발명의 조성물은 소량의 pH 완충제(buffer)를 포함할 수 있다. 구체적으로 상기 pH 완충제(buffer)의 함량은 조성물 기준으로 0.1 - 30mM, 0.1 - 25mM, 0.1 - 20mM, 0.1 - 17mM, 0.1 - 15mM, 0.1 - 13mM, 0.1 - 10mM, 0.1 - 7mM, 또는 0.1 - 5mM의 농도로 첨가될 수 있다. The fact that the composition of the present invention does not use the pH buffer substantially means that the composition of the present invention does not substantially contain the pH buffer, so that the electrical conductivity at 25° C. satisfies 5 mS/cm or less. The composition of the present invention may contain a small amount of a pH buffer, provided that the composition of the present invention has an electrical conductivity of 5 mS/cm or less at 25°C. Specifically, the content of the pH buffer is 0.1 - 30mM, 0.1 - 25mM, 0.1 - 20mM, 0.1 - 17mM, 0.1 - 15mM, 0.1 - 13mM, 0.1 - 10mM, 0.1 - 7mM, or 0.1 - 5mM based on the composition may be added at a concentration of
본 발명에 따른 상기 데옥시콜린산(DCA)을 함유하는 약제학적 조성물은 종래의 데옥시콜린산(DCA)을 함유하는 약제학적 조성물에 비하여 낮은 pH인 pH 8.0 이하에도 불구하고 보관 기간 동안 침전물이 발생하지 않고 우수한 보관 안정성을 나타낼 수 있다. 또한, 낮은 pH를 가짐에 따라 인체 내 pH인 pH 7.4와 유사해지고, 주사 부위 국소 pH의 회복이 빨라져 주사 통증을 현저히 완화할 수 있고, 투여 부위에서 작열감, 염증 등의 부작용이 발생하는 것을 최소화할 수 있다. The pharmaceutical composition containing deoxycholic acid (DCA) according to the present invention has a lower pH than that of the conventional pharmaceutical composition containing deoxycholic acid (DCA), despite the lower pH of 8.0 or less during the storage period. It does not occur and can exhibit excellent storage stability. In addition, as it has a low pH, it becomes similar to pH 7.4, which is the pH of the human body, and the recovery of the local pH at the injection site is accelerated, so that the injection pain can be significantly alleviated, and the occurrence of side effects such as burning sensation and inflammation at the injection site can be minimized. can
또한, 본 발명에 따른 상기 데옥시콜린산(DCA)을 함유하는 약제학적 조성물에 있어서, 상기 첨가제는 폴리올(polyol), 아미노산(amino acid) 및 비이온성 계면활성제(non-ionic surfactant)로 이루어진 군에서 선택된 적어도 하나 이상을 포함할 수 있다. 종래에는 첨가제로서 등장화제(isotonic agent) 역할을 하는 염화나트륨과 같은 이온성 물질이 주로 사용되었으나, 본 발명의 일 실시예에 따른 약제학적 조성물은 첨가제로서 염화나트륨과 같은 이온성 물질을 대신하여 폴리올(polyol), 아미노산(amino acid) 및 비이온성 계면활성제(non-ionic surfactant)로 이루어진 군에서 선택된 적어도 하나 이상을 사용할 수 있다. 이에 따라, 종래처럼 이온성 물질을 사용하는 경우보다 전기전도도가 낮을 수 있으며, 25℃에서 전기전도도가 5mS/cm 이하를 만족할 수 있다. 보다 구체적으로는, 25℃에서 전기전도도가 0.1mS/cm 내지 5mS/cm, 더 구체적으로 25℃에서 전기전도도가 0.1mS/cm 내지 4mS/cm, 보다 더 구체적으로 0.1mS/cm 내지 3mS/cm일 수 있다. 이와 같은 본 발명의 일 실시예에 따른 약제학적 조성물은 낮은 pH에도 불구하고 침전 및 겔화를 효과적으로 방지할 수 있어 보관 안정성이 향상된다. In addition, in the pharmaceutical composition containing deoxycholic acid (DCA) according to the present invention, the additive is a polyol (polyol), amino acid (amino acid) and a group consisting of a non-ionic surfactant (non-ionic surfactant) It may include at least one or more selected from. Conventionally, an ionic substance such as sodium chloride serving as an isotonic agent has been mainly used as an additive, but the pharmaceutical composition according to an embodiment of the present invention is a polyol (polyol) instead of an ionic substance such as sodium chloride as an additive. ), amino acids and at least one selected from the group consisting of non-ionic surfactants may be used. Accordingly, the electrical conductivity may be lower than that in the case of using an ionic material as in the prior art, and the electrical conductivity may satisfy 5 mS/cm or less at 25°C. More specifically, the electrical conductivity at 25° C. is 0.1 mS/cm to 5 mS/cm, more specifically, the electrical conductivity is 0.1 mS/cm to 4 mS/cm at 25° C., and even more specifically, 0.1 mS/cm to 3 mS/cm can be As such, the pharmaceutical composition according to an embodiment of the present invention can effectively prevent precipitation and gelation in spite of a low pH, thereby improving storage stability.
상기 폴리올은 다수의 하이드록실 그룹(hydroxyl group)을 갖는 물질로써 당(환원 및 비환원), 당 알코올을 포함할 수 있다. 폴리올의 비제한적인 예로서, 수크로오스(sucrose), 글리세롤(glycerol), 만니톨(mannitol), 소르비톨(sorbitol), 프로필렌글리콜(propylene glycol), 트레할로스(trehalose), 에틸렌글리콜(ethyleneglycol), 말토스(maltose), 글루코스(glucose) 및 폴리에틸렌글리콜(polyethyleneglycol)로 이루어진 군에서 선택된 적어도 하나 이상일 수 있으며, 침전 및 겔화 방지 효과를 고려했을 때 보다 바람직하게는 수크로오스(sucrose), 글리세롤(glycerol) 및 만니톨(mannitol) 중에서 적어도 하나 이상일 수 있으나, 이에 한정되지 않는다. The polyol is a material having a plurality of hydroxyl groups, and may include sugars (reduced and non-reduced) and sugar alcohols. Non-limiting examples of polyols include sucrose, glycerol, mannitol, sorbitol, propylene glycol, trehalose, ethylene glycol, maltose ), may be at least one selected from the group consisting of glucose and polyethylene glycol, and more preferably sucrose, glycerol and mannitol in consideration of the effect of preventing precipitation and gelation. It may be at least one of them, but is not limited thereto.
상기 아미노산은 히스티딘(histidine), 메티오닌(methionine), 글리신(glycine), 알라닌(alanine), 발린(valine), 류신(leucine), 이소류신(isoleucine), 티로신(tyrosine), 프롤린(proline), 페닐알라닌(phenylalanine), 아스파라진(asparagine), 글루타민(glutamine), 세린(serine), 트레오닌(threonine), 시스테인(cysteine) 및 트립토판(tryptophane)으로 이루어진 군에서 선택된 적어도 하나 이상일 수 있으며, 침전 및 겔화 방지 효과를 고려했을 때 보다 바람직하게는 히스티딘(histidine) 및/또는 메티오닌(methionine)일 수 있으나, 이에 한정되지 않는다. The amino acids are histidine, methionine, glycine, alanine, valine, leucine, isoleucine, tyrosine, proline, phenylalanine ( It may be at least one selected from the group consisting of phenylalanine, asparagine, glutamine, serine, threonine, cysteine and tryptophane, and has an effect of preventing precipitation and gelation More preferably, it may be histidine and/or methionine, but is not limited thereto.
상기 비이온성 계면활성제는 폴록사머(poloxamer) 및 폴리소르베이트(polysorbate)로 이루어진 군에서 선택된 적어도 하나 이상일 수 있으며, 예를 들어, 폴록사며 188, 폴리소르베이트(polysorbate) 20, 폴리소르베이트(polysorbate) 80 등을 사용할 수 있으나, 이에 한정되지 않는다. The nonionic surfactant may be at least one selected from the group consisting of poloxamer and polysorbate, for example, poloxamer 188, polysorbate 20, polysorbate ) 80, etc. may be used, but is not limited thereto.
본 발명의 일 실시예에 따른 상기 데옥시콜린산(DCA)을 함유하는 약제학적 조성물은 침전 및 겔화 방지 효과를 고려했을 때 가장 바람직하게는 수크로오스(sucrose), 글리세롤(glycerol) 및 만니톨(mannitol) 중 적어도 하나 이상을 사용할 수 있다. The pharmaceutical composition containing deoxycholic acid (DCA) according to an embodiment of the present invention is most preferably sucrose, glycerol and mannitol in consideration of the effect of preventing precipitation and gelation. At least one or more of them may be used.
본 발명의 일 실시예에 따른 상기 데옥시콜린산(DCA)을 함유하는 약제학적 조성물은 상기 폴리올(polyol), 아미노산(amino acid) 및 비이온성 계면활성제(non-ionic surfactant)로 이루어진 군에서 선택된 적어도 하나 이상의 첨가제를 0.1 내지 500mM, 바람직하게는 0.1 내지 400mM로 포함할 수 있으며, 보다 바람직하게는 0.3 내지 350mM, 0.3 내지 300mM, 0.3 내지 250mM, 또는 0.3 내지 230mM을 포함할 수 있다. 상기 범위 내로 상기 첨가제를 함유함으로써 조성물의 삼투압을 체액과 유사하게 구성할 수 있다. The pharmaceutical composition containing deoxycholic acid (DCA) according to an embodiment of the present invention is selected from the group consisting of the polyol, amino acid and non-ionic surfactant. At least one additive may be included in an amount of 0.1 to 500 mM, preferably 0.1 to 400 mM, and more preferably 0.3 to 350 mM, 0.3 to 300 mM, 0.3 to 250 mM, or 0.3 to 230 mM. By containing the additive within the above range, the osmotic pressure of the composition may be similar to that of body fluid.
본 발명의 데옥시콜린산(DCA)를 함유하는 약제학적 조성물이 상기 폴리올을 포함하는 경우, 특히 폴리올로서 수크로오스, 글리세롤 및 만니톨 중 적어도 하나 이상을 포함하는 경우, 25℃에서 전기전도도가 5mS/cm 이하인 범위내에서 pH 조절제 또는 pH 완충제(buffer)를 더 포함할 수 있다. 상기 더 첨가되는 pH 조절제 또는 pH 완충제(buffer)는 시트르산나트륨, 수산화나트륨, 아디프산, 시트르산, 인산, 소듐포스페이트, 디소듐포스페이트, 모노나트륨인산염, 무수인산수소나트륨, 탄산칼슘, 수산화칼슘, 젖산칼슘, 말레산, 말산, 글루탐산나트륨, 아세트산나트륨, 탄산수소나트륨, 시트르산삼나트륨, 소듐락테이트, 및 트리에탄올아민으로 이루어지는 군에서 선택되는 적어도 하나 이상일 수 있으며, 침전 및 겔화 방지 효과를 고려하였을 때 모노나트륨인산염 및/또는 시트르산나트륨일 수 있다. 상기 더 첨가되는 pH 조절제 또는 pH 완충제의 양은 본 발명의 조성물이 25℃에서 전기전도도가 5mS/cm 이하가 되는 범위내에서 첨가될 수 있으며, 구체적으로 최종 조성물 기준으로 0.1 - 30mM, 0.1 - 25mM, 0.1 - 20mM, 0.1 - 17mM, 0.1 - 15mM, 0.1 - 13mM, 0.1 - 10mM, 0.1 - 7mM, 또는 0.1 - 5mM의 농도로 첨가될 수 있다. When the pharmaceutical composition containing deoxycholic acid (DCA) of the present invention includes the polyol, in particular, when it includes at least one of sucrose, glycerol and mannitol as the polyol, the electrical conductivity at 25° C. is 5 mS/cm It may further include a pH adjusting agent or a pH buffer (buffer) within the following range. The further added pH adjusting agent or pH buffer (buffer) is sodium citrate, sodium hydroxide, adipic acid, citric acid, phosphoric acid, sodium phosphate, disodium phosphate, monosodium phosphate, anhydrous sodium hydrogen phosphate, calcium carbonate, calcium hydroxide, calcium lactate , maleic acid, malic acid, sodium glutamate, sodium acetate, sodium hydrogen carbonate, trisodium citrate, sodium lactate, and may be at least one selected from the group consisting of triethanolamine, monosodium when considering the effect of preventing precipitation and gelation phosphate and/or sodium citrate. The amount of the further added pH adjusting agent or pH buffering agent may be added within the range that the composition of the present invention has an electrical conductivity of 5 mS/cm or less at 25° C., specifically 0.1-30 mM, 0.1-25 mM, based on the final composition, 0.1 - 20 mM, 0.1 - 17 mM, 0.1 - 15 mM, 0.1 - 13 mM, 0.1 - 10 mM, 0.1 - 7 mM, or 0.1 - 5 mM.
한편, 본 발명에 따른 상기 데옥시콜린산(DCA)을 함유하는 약제학적 조성물은 벤질알코올을 포함하지 않을 수 있다. 또한, 본 발명에 따른 상기 데옥시콜린산(DCA)을 함유하는 약제학적 조성물은 염화 벤잘코늄, 염화 벤잘토늄, 페놀, 크레솔, 클로로크레솔 및 클로로부탄올을 포함하지 않을 수 있다. 종래에 데옥시콜린산(DCA)을 함유하는 수용성 용액들은 보존제로서 벤질 알코올을 많이 사용하여 왔는데, 벤질 알코올을 포함하는 수용성 용액들에서 데옥시콜린산의 낮은 농도는 일정 기간 동안 보관 이후에 침전물이 발생하는 경우가 많으며, 특히, 벤질 알코올은 피부에 접촉시 자극을 일으킬 수 있어 문제가 있었다. 또한, 벤질 알코올의 이러한 문제점들 때문에 벤질 알코올을 대신하여 보존제로서 염화 벤잘코늄, 염화 벤잘토늄, 페놀, 크레졸, 클로로크레솔 및 클로로부탄올을 포함하는 종래에 데옥시콜린산(DCA)을 함유하는 수용성 용액의 경우가 있다. 그러나, 미생물을 죽이거나 번식을 막는 보존제의 특성상 여러 실험 및 임상 연구에서 보존제에 노출시 인체 자극 및 독성이 있는 것으로 알려져 있다. 이에, 단회 투여 제형의 경우 상기와 같은 보존제를 사용하지 않는 것이 더욱 바람직할 수 있다. On the other hand, the pharmaceutical composition containing deoxycholic acid (DCA) according to the present invention may not contain benzyl alcohol. In addition, the pharmaceutical composition containing deoxycholic acid (DCA) according to the present invention may not contain benzalkonium chloride, benzaltonium chloride, phenol, cresol, chlorocresol and chlorobutanol. Conventionally, aqueous solutions containing deoxycholic acid (DCA) have often used benzyl alcohol as a preservative, but the low concentration of deoxycholic acid in aqueous solutions containing benzyl alcohol causes the precipitate to form after storage for a certain period of time. It occurs in many cases, and in particular, benzyl alcohol may cause irritation when in contact with the skin, so there is a problem. In addition, because of these problems of benzyl alcohol, water-soluble containing deoxycholic acid (DCA) conventionally containing benzalkonium chloride, benzaltonium chloride, phenol, cresol, chlorocresol and chlorobutanol as preservatives instead of benzyl alcohol There is a case for a solution. However, due to the nature of preservatives that kill microorganisms or prevent reproduction, it is known that exposure to preservatives is irritating and toxic to the human body in several experiments and clinical studies. Therefore, in the case of a single dose formulation, it may be more preferable not to use the preservative as described above.
이에, 본 발명에 따른 상기 데옥시콜린산(DCA)을 함유하는 약제학적 조성물은 벤질알코올을 포함하지 않을 수 있으며, 염화 벤잘코늄, 염화 벤잘토늄, 페놀, 크레졸, 클로로크레솔 및 클로로부탄올을 포함하지 않을 수 있다. 이에 따라, 보관시 침전 및 겔화 발생을 효과적으로 억제할 수 있으며, 피부 접촉시 피부 자극을 줄이고, 제제에 의한 잠재적인 독성 위험을 줄일 수 있다. Accordingly, the pharmaceutical composition containing deoxycholic acid (DCA) according to the present invention may not contain benzyl alcohol, and may contain benzalkonium chloride, benzaltonium chloride, phenol, cresol, chlorocresol and chlorobutanol. may not Accordingly, it is possible to effectively suppress the occurrence of precipitation and gelation during storage, reduce skin irritation upon skin contact, and reduce the risk of potential toxicity due to the formulation.
본 발명에 따른 상기 데옥시콜린산(DCA)을 함유하는 약제학적 조성물은 지방분해에 사용될 수 있으며, 비만의 예방 또는 치료에 사용될 수 있다.The pharmaceutical composition containing deoxycholic acid (DCA) according to the present invention can be used for lipolysis, and can be used for the prevention or treatment of obesity.
또한, 본 발명은 지방분해의 유도 혹은 비만의 치료를 필요로 하는 포유동물에게 치료학적으로 유효한 양의 상기 데옥시콜린산 또는 이의 약제학적으로 허용 가능한 염을 포함하는 약제학적 조성물을 투여하는, 지방분해 유도방법 혹은 비만의 치료방법을 포함할 수 있다.In addition, the present invention provides a method for administering a pharmaceutical composition comprising a therapeutically effective amount of deoxycholic acid or a pharmaceutically acceptable salt thereof to a mammal in need of induction of lipolysis or treatment of obesity. It may include a method for inducing the risk of obesity or a method for treating obesity.
또한, 본 발명은 지방분해 유도 혹은 비만의 예방 또는 치료를 위한 약제의 제조에 있어서의 사용을 위한 상기 데옥시콜린산 또는 이의 약제학적으로 허용 가능한 염을 포함하는 약제학적 조성물의 용도를 제공한다.In addition, the present invention provides the use of a pharmaceutical composition comprising the deoxycholic acid or a pharmaceutically acceptable salt thereof for use in the manufacture of a medicament for the prevention or treatment of lipolysis induction or obesity.
상기 "치료"란 발병 증상을 보이는 객체에 사용될 때 질병의 진행을 중단 또는 지연시키는 것을 의미하며, 상기 "예방"이란 발병 증상을 보이지는 않지만 그러한 위험성이 높은 객체에 사용될 때 발병 징후를 중단 또는 지연시키는 것을 의미한다. The "treatment" means stopping or delaying the progression of a disease when used in a subject showing symptoms of onset, and the term "prevention" means stopping or delaying symptoms of an onset when used in a subject that does not show symptoms of onset, but at a high risk of such disease. means to do
이하, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 본 발명의 실시예에 대하여 상세히 설명한다. 그러나 본 발명은 여러 가지 상이한 형태로 구현될 수 있으며 여기에서 설명하는 실시예에 한정되지 않는다. Hereinafter, embodiments of the present invention will be described in detail so that those of ordinary skill in the art can easily carry out the present invention. However, the present invention may be embodied in many different forms and is not limited to the embodiments described herein.
[실험예 1: pH 완충능 비교 실험] [Experimental Example 1: pH buffering capacity comparison experiment]
주사용수에 10mM 소듐 포스페이트(sodium phosphate), 10mM 트리스(TRIS), 10mg/mL의 데옥시콜린산(Sigma-aldrich사로부터 입수)을 각각 용해시킨 후, NaOH 수용액 또는 HCl 수용액을 가하여 pH를 7.5로 적정하였다. (데옥시콜린산 용해시에는 NaOH 수용액을 소량씩 가하여 데옥시콜린산이 완전히 용해된 후 이후 HCl 수용액을 가하여 pH 적정하였다.) 이후, pH 7.5에서 7.0 구간의 완충능을 확인하기 위하여 40mL의 용액을 취하여 0.5M HCl을 40㎕씩 첨가하며 pH를 측정하였다. 또한, pH 7.5에서 8.0 구간의 완충능을 확인하기 위하여 40mL의 용액을 취하고 0.5M NaOH를 40㎕씩 첨가하며 pH를 측정하였다. 각 용액의 완충능을 계산하기 위하여 pH의 변화량에 대한 첨가한 염기 또는 산의 양을 선형회귀분석하여 두 변수 사이의 기울기를 도출하였다. 그 결과를 표 1, 도 1 및 도 2에 나타내었다. After dissolving 10 mM sodium phosphate, 10 mM tris (TRIS), and 10 mg/mL deoxycholic acid (obtained from Sigma-aldrich) in water for injection, respectively, NaOH aqueous solution or HCl aqueous solution was added to adjust the pH to 7.5. Titrated. (When dissolving deoxycholic acid, a small amount of NaOH aqueous solution was added to completely dissolve deoxycholic acid, and then an aqueous HCl solution was added to adjust the pH.) Then, 40 mL of the solution was added to check the buffering capacity of the pH 7.5 to 7.0 section. The pH was measured by adding 0.5M HCl by 40 μl. In addition, in order to check the buffering capacity of the pH 7.5 to 8.0 section, 40 mL of the solution was taken, and 0.5M NaOH was added by 40 μl to measure the pH. In order to calculate the buffering capacity of each solution, the slope between the two variables was derived by linear regression analysis of the amount of added base or acid with respect to the change in pH. The results are shown in Table 1, FIGS. 1 and 2 .
표 1, 도 1 및 도 2를 참조하면, pH 8.0 부근에서 흔히 사용되는 소듐 포스페이트(sodium phosphate), 트리스(TRIS) pH 완충제(buffer)와 10mg/mL의 데옥시콜린산(DCA)이 유사한 정도의 완충능을 나타내는 것을 확인하였으며, 특히, pH 7.5-7.0 구간에서 10mg/mL의 데옥시콜린산(DCA)의 pH 완충능이 우수하게 나타났다. Referring to Table 1, Figure 1 and Figure 2, sodium phosphate (sodium phosphate), tris (TRIS) pH buffer and 10mg/mL deoxycholic acid (DCA) commonly used in the vicinity of pH 8.0 are similar. It was confirmed that the buffering capacity of , in particular, the pH buffering capacity of 10 mg / mL of deoxycholic acid (DCA) in the pH 7.5-7.0 range was excellent.
실시예 1Example 1
약 25∼30℃의 주사용수 80-85 ml에 데옥시콜린산(Sigma-aldrich사로부터 입수)을 25mg/mL을 첨가한 후, 300rpm으로 교반하면서 데옥시콜린산이 용해되도록 6N 수산화나트륨 수용액을 소량씩 가하였다. 육안으로 확인하여 데옥시콜린산이 모두 용해된 후 300rpm으로 약 30분 동안 추가 교반하여 충분히 용해시켰다. 얻어진 용액의 pH를 0.5N 염산으로 pH 8.0으로 조절한 다음, 주사용수로 최종 부피 100ml을 맞췄다. 멤브레인 필터(PES 0.22μm 필터, Millipore, USA)로 제균 여과한 후 바이알에 충진하고 5℃에 보관하였다. 25℃ 전기전도도는 4.9mS/cm였다.After adding 25 mg/mL of deoxycholic acid (obtained from Sigma-aldrich) to 80-85 ml of water for injection at about 25-30° C., stirring at 300 rpm, add a small amount of 6N sodium hydroxide aqueous solution to dissolve deoxycholic acid. added each. After confirming with the naked eye, all deoxycholic acid was dissolved, followed by further stirring at 300 rpm for about 30 minutes to sufficiently dissolve. The pH of the obtained solution was adjusted to pH 8.0 with 0.5N hydrochloric acid, and then adjusted to a final volume of 100 ml with water for injection. After sterilization and filtration with a membrane filter (PES 0.22 μm filter, Millipore, USA), it was filled in a vial and stored at 5°C. The electrical conductivity at 25°C was 4.9 mS/cm.
비교예 1Comparative Example 1
pH를 8.0으로 조절한 다음 소듐 포스페이트(sodium phosphate)를 20mM 더 첨가한 것을 제외하고는 실시예 1과 동일하게 제조하였다. 25℃ 전기전도도는 9.1mS/cm였다. After adjusting the pH to 8.0, it was prepared in the same manner as in Example 1, except that 20 mM of sodium phosphate was further added. The electrical conductivity at 25°C was 9.1 mS/cm.
비교예 2Comparative Example 2
pH를 8.0으로 조절한 다음 트리스(TRIS)를 20mM 더 첨가한 것을 제외하고는 실시예 1과 동일하게 제조하였다. 25℃ 전기전도도는 5.6mS/cm였다. After adjusting the pH to 8.0, it was prepared in the same manner as in Example 1, except that 20 mM of TRIS was further added. The electrical conductivity at 25°C was 5.6 mS/cm.
비교예 3Comparative Example 3
pH를 8.0으로 조절한 다음 소듐 비카보네이트(sodium bicarbonate)를 20mM 더 첨가한 것을 제외하고는 실시예 1과 동일하게 제조하였다. 25℃ 전기전도도는 9.0mS/cm였다. After adjusting the pH to 8.0, it was prepared in the same manner as in Example 1, except that 20 mM of sodium bicarbonate was further added. The electrical conductivity at 25°C was 9.0 mS/cm.
[실험예 1: 보관 안정성 실험][Experimental Example 1: Storage stability test]
실시예 1, 비교예 1~3에서 제조한 제제를 5℃ 챔버에서 불출한 직후, 25℃ 1시간 상온화 후 침전 및 겔화 여부를 비교하였다. 그 결과를 표 2에 나타내었다.Immediately after dispensing the formulations prepared in Example 1 and Comparative Examples 1 to 3 from the chamber at 5° C., after room temperature at 25° C. for 1 hour, precipitation and gelation were compared. The results are shown in Table 2.
* 0: 훈련된 작업자가 육안으로 확인할 수 있는 침전이나 겔(gel) 없음* 0: No sediment or gel visible to the naked eye by trained operators
1: 훈련된 작업자가 육안으로 확인할 수 있는 침전이나 겔(gel) 있음1: Has sediment or gel visible to the naked eye by trained operators
2: 훈련되지 않은 작업자가 육안으로 수초 내로 확인할 수 있는 수준의 침전이나 겔(gel) 있음2: There is a level of sediment or gel visible to the naked eye within seconds by an untrained operator
3: 훈련되지 않은 작업자가 육안으로 바로 확인할 수 있는 수준의 침전이나 겔(gel) 있음 3: There is a level of sediment or gel visible to the naked eye by an untrained operator
상기 표 2를 참조하면, pH 완충제(buffer)를 사용하여 전기전도도가 5mS/cm를 초과하는 비교예 1~3의 경우 침전 및/또는 겔(gel)화가 발생된 반면에, pH 완충제(buffer)를 사용하지 않고, 전기전도도가 5mS/cm 이하인 실시예 1의 경우 불출 직후 및 상온화 후에도 침전 및/또는 겔(gel)화가 발생하지 않은 것을 확인할 수 있다. Referring to Table 2, in the case of Comparative Examples 1 to 3, in which the electrical conductivity exceeds 5 mS/cm using a pH buffer, precipitation and/or gelation occurred while the pH buffer was used. In the case of Example 1, in which the electrical conductivity is 5 mS/cm or less without using , it can be confirmed that precipitation and/or gelation did not occur immediately after dispensing and after room temperature.
실시예 2~6, 비교예 4Examples 2 to 6, Comparative Example 4
약 25∼30℃의 주사용수 80-85 ml에 데옥시콜린산(Sigma-aldrich사로부터 입수)을 10mg/mL을 첨가한 후, 300rpm으로 교반하면서 데옥시콜린산이 용해되도록 6N 수산화나트륨 수용액을 소량씩 가하였다. 육안으로 확인하여 데옥시콜린산이 모두 용해된 후 300rpm으로 약 30분 동안 추가 교반하여 충분히 용해시켰다. 얻어진 용액의 pH를 0.5N 염산으로 pH 7.5로 조절한 다음, 하기 표 3과 같이 첨가제를 첨가하여 녹이고, 주사용수로 최종 부피 100ml을 맞췄다. 멤브레인 필터(PES 0.22μm 필터, Millipore, USA)로 제균 여과한 후 바이알에 충진하고 5℃에 보관하였다. After adding 10 mg/mL of deoxycholic acid (obtained from Sigma-aldrich) to 80-85 ml of water for injection at about 25-30° C., stirring at 300 rpm, add a small amount of 6N sodium hydroxide aqueous solution to dissolve deoxycholic acid. added each. After confirming with the naked eye, all deoxycholic acid was dissolved, followed by further stirring at 300 rpm for about 30 minutes to sufficiently dissolve. The pH of the obtained solution was adjusted to pH 7.5 with 0.5N hydrochloric acid, and then added and dissolved as shown in Table 3 below, and the final volume was adjusted to 100 ml with water for injection. After sterilization and filtration with a membrane filter (PES 0.22 μm filter, Millipore, USA), it was filled in a vial and stored at 5°C.
비교예 5Comparative Example 5
약 25∼30℃의 주사용수 80-85 ml에 소듐 포스페이트 디베이직(sodium phosphate dibasic)을 1.42mg/mL이 되도록, 수산화나트륨을 1.43mg/mL이 되도록 첨가하여 20분동안 교반시켰다. 데옥시콜린산(Sigma-aldrich사로부터 입수)을 10mg/mL가 되도록 첨가한 후, 300rpm으로 약 60분 동안 교반하여 충분히 용해시켰다. 얻어진 용액의 pH를 0.5N 염산으로 pH 7.5로 조절한 다음, 첨가제로서 염화나트륨 4.38mg/mL, 벤질 알코올 9mg/mL을 첨가하고 약 10분 동안 충분히 교반하여 용해시켰다. 주사용수로 최종 부피 100ml을 맞췄다. 멤브레인 필터(PES 0.22μm 필터, Millipore, USA)로 제균 여과한 후 바이알에 충진하고 5℃에 보관하였다. Sodium phosphate dibasic (sodium phosphate dibasic) was added to 1.42 mg/mL and sodium hydroxide to 1.43 mg/mL to 80-85 ml of water for injection at about 25-30°C, followed by stirring for 20 minutes. Deoxycholic acid (obtained from Sigma-aldrich) was added to a concentration of 10 mg/mL, followed by stirring at 300 rpm for about 60 minutes to fully dissolve. The pH of the obtained solution was adjusted to pH 7.5 with 0.5N hydrochloric acid, and then sodium chloride 4.38 mg/mL and benzyl alcohol 9 mg/mL were added as additives, and dissolved by stirring sufficiently for about 10 minutes. The final volume was adjusted to 100 ml with water for injection. After sterilization and filtration with a membrane filter (PES 0.22 μm filter, Millipore, USA), it was filled in a vial and stored at 5°C.
[실험예 2: 보관 안정성 실험][Experimental Example 2: Storage Stability Test]
실시예 2~6, 비교예 4~5에서 제조한 제제를 5℃에서 2개월 보관한 후 침전 및 겔화 여부를 비교하였다. 그 결과를 표 3에 나타내었다. After storing the formulations prepared in Examples 2 to 6 and Comparative Examples 4 to 5 at 5° C. for 2 months, precipitation and gelation were compared. The results are shown in Table 3.
50mMNaCl
50 mM
74.9mMNaCl
74.9 mM
(mS/cm)electrical conductivity
(mS/cm)
(mOsm/kg)osmotic pressure
(mOsm/kg)
여부*Precipitation occurs after 2 months at 5℃
Whether*
* 0: 훈련된 작업자가 육안으로 확인할 수 있는 침전이나 겔(gel) 없음 * 0: No sediment or gel visible to the naked eye by trained operators
1: 훈련된 작업자가 육안으로 확인할 수 있는 침전이나 겔(gel) 있음 1: Has sediment or gel visible to the naked eye by trained operators
2: 훈련되지 않은 작업자가 육안으로 수초 내로 확인할 수 있는 수준의 침전이나 겔(gel) 있음 2: There is a level of sediment or gel visible to the naked eye within seconds by an untrained operator
3: 훈련되지 않은 작업자가 육안으로 바로 확인할 수 있는 수준의 침전이나 겔(gel) 있음 3: There is a level of sediment or gel visible to the naked eye by an untrained operator
** Poloxamer188은 평균 분자량인 8400dalton으로 5mg/mL을 몰농도로 환산** Poloxamer188 has an average molecular weight of 8400 daltons, and 5 mg/mL is converted into molar concentration.
표 3을 참조하면, 첨가제로 NaCl과 같은 이온성 물질을 사용한 비교예 4는 침전이 발생한 반면에, 첨가제로서 폴리올, 아미노산, 비이온성 계면활성제의 첨가제를 사용한 실시예 2~6의 경우 pH 7.5에서도 침전이 발생하지 않은 것을 확인할 수 있었다. Referring to Table 3, in Comparative Example 4 using an ionic material such as NaCl as an additive, precipitation occurred, whereas in Examples 2 to 6 using an additive of a polyol, an amino acid, and a nonionic surfactant as an additive, even at pH 7.5 It was confirmed that no precipitation occurred.
실시예 7~22Examples 7-22
하기 표 4와 같이 첨가제를 첨가하고, pH를 조절한 것을 제외하고는 실시예 2와 동일하게 제조하였다. It was prepared in the same manner as in Example 2, except that additives were added as shown in Table 4 below and the pH was adjusted.
비교예 6Comparative Example 6
pH를 8.3으로 조절한 것을 제외하고는 비교예 5와 동일하게 제조하였다.It was prepared in the same manner as in Comparative Example 5, except that the pH was adjusted to 8.3.
비교예 7Comparative Example 7
벤질 알코올을 포함하지 않은 것을 제외하고는 비교예 5와 동일하게 제조하였다. It was prepared in the same manner as in Comparative Example 5 except that benzyl alcohol was not included.
비교예 8Comparative Example 8
약 25∼30℃의 주사용수 80-85 ml에 소듐 포스페이트 디베이직(sodium phosphate dibasic) 1.42mg/mL를 첨가하여 20분 동안 교반시켰다. 얻어진 용액에 수산화나트륨이 최종 부피 기준 약 1.07mg/mL가 되도록 용해시킨 후, 데옥시콜린산(Sigma-aldrich사로부터 입수)을 10mg/mL 첨가한 후, 300rpm으로 약 60분 동안 교반하여 용해시켰다. 얻어진 용액의 pH를 염산으로 pH 8.3으로 조절한 다음, 첨가제로서 염화나트륨이 최종 부피 기준 147mM이 되도록 첨가하고 주사용수로 최종 부피 100ml을 맞췄다. 멤브레인 필터(PES 0.22μm 필터, Millipore, USA)로 여과한 후 바이알에 충진하였다. 충진한 바이알을 5℃에 보관하였다. Sodium phosphate dibasic (sodium phosphate dibasic) 1.42 mg/mL was added to 80-85 ml of water for injection at about 25-30° C. and stirred for 20 minutes. Sodium hydroxide was dissolved in the resulting solution to about 1.07 mg/mL by final volume, and then 10 mg/mL of deoxycholic acid (obtained from Sigma-aldrich) was added, followed by stirring at 300 rpm for about 60 minutes to dissolve. . The pH of the obtained solution was adjusted to pH 8.3 with hydrochloric acid, and then sodium chloride as an additive was added to a final volume of 147 mM, and the final volume was adjusted to 100 ml with water for injection. After filtration with a membrane filter (PES 0.22 μm filter, Millipore, USA), it was filled into a vial. The filled vials were stored at 5°C.
비교예 9Comparative Example 9
pH를 7.5로 조절한 것을 제외하고는 비교예 8과 동일하게 제조하였다.It was prepared in the same manner as in Comparative Example 8, except that the pH was adjusted to 7.5.
(mM)Met
(mM)
(mM)P188**
(mM)
(mM)PS20
(mM)
(mOsm/kg)osmotic pressure
(mOsm/kg)
* Met: 메티오닌(methionine)* Met: methionine
P188: 폴록사머 188(poloxamer 188) P188: poloxamer 188 (poloxamer 188)
PS20: 폴리소르베이트20(polysorbate 20) PS20: polysorbate 20 (polysorbate 20)
** Poloxamer188은 평균 분자량인 8400dalton으로 5mg/mL을 몰농도로 환산** Poloxamer188 has an average molecular weight of 8400 daltons, and 5 mg/mL is converted into molar concentration.
[실험예 3: 보관 안정성 실험][Experimental Example 3: Storage stability test]
실시예 7~22, 비교예 5~9에서 제조한 제제를 바이알(vial) 또는 시린지(syringe)에 충전하여 5℃에서 11일, 1개월, 2개월 보관한 후 불출 직후 및 25℃로 상온화 후의 침전 및 겔화 여부를 비교하였다. 그 결과를 표 5에 나타내었다. The formulations prepared in Examples 7 to 22 and Comparative Examples 5 to 9 were filled in vials or syringes and stored at 5° C. for 11 days, 1 month, and 2 months, immediately after dispensing and at room temperature at 25° C. After precipitation and gelation were compared. The results are shown in Table 5.
(불출직후/상온화후)vial
(immediately after dispensing / after warming to room temperature)
(불출직후/상온화후)syringe
(immediately after dispensing / after warming to room temperature)
(불출직후/상온화후)vial
(immediately after dispensing / after warming to room temperature)
(불출직후/상온화후)syringe
(immediately after dispensing / after warming to room temperature)
(불출직후/상온화후)vial
(immediately after dispensing / after warming to room temperature)
(불출직후/상온화후)syringe
(immediately after dispensing / after warming to room temperature)
* - : 겔(gel) 및 침전이 없음 * - : No gel and no precipitation
표 5를 참조하면, 실시예 7~22의 경우는 11일, 1개월, 2개월 보관 후 불출 직후 및 상온화 후에 바이알 및 시린지에서 모두 겔(gel) 및 침전이 발생하지 않은 것을 확인할 수 있다. 실시예 7~22의 경우 벤질 알코올을 포함하지 않고, pH가 체내와 유사하기 때문에 안전성과 투여시 통증 측면에서 우수할 것으로 보인다.Referring to Table 5, in the case of Examples 7 to 22, it can be seen that gel and precipitation did not occur in both the vial and syringe immediately after discharge and after room temperature after storage for 11 days, 1 month, and 2 months. Examples 7 to 22 do not contain benzyl alcohol, and because the pH is similar to that of the body, it is expected to be excellent in terms of safety and pain during administration.
반면에, 비교예 5~9를 살펴보면, 벤질 알코올이 겔화/침전 방지에 효과가 있음을 확인하였으나, 벤질 알코올은 유럽의 몇몇 국가를 포함한 국가들에서 안전성의 이슈가 있다. 한편, 바이알 대비 시린지에서 침전 발생 정도가 적은 것을 확인할 수 있었다. On the other hand, looking at Comparative Examples 5 to 9, it was confirmed that benzyl alcohol is effective in preventing gelation/precipitation, but benzyl alcohol has a safety issue in countries including some European countries. On the other hand, it was confirmed that the degree of precipitation was less in the syringe compared to the vial.
실시예 23-34Examples 23-34
약 25∼30℃의 주사용수 80-85ml에 최종 농도 기준으로 수산화나트륨을 1.07mg/mL, 데옥시콜린산(DCA, Sigma-aldrich사로부터 입수)을 10mg/mL가 되도록 첨가한 후, 300rpm으로 약 20분 동안 교반하여 충분히 용해시켰다. 얻어진 용액에 소듐 포스페이트 모노베이직(sodium phosphate monobasic), 소듐 시트레이트(sodium citrate), 글리세롤(glycerol), 수크로오스(sucrose)를 하기 표 6에 따른 농도로 첨가하고 추가 교반하여 모두 용해시켰다. 이어서, 필요 시 1N 수산화나트륨을 소량씩 가하여 pH를 하기 표 6에 나타낸 바와 같이 조절한 후 주사용수로 최종 부피 100ml을 맞췄다. 멤브레인 필터(PES 0.22μm 필터, Millipore, USA)로 제균 여과한 후 바이알에 충진하고 55℃에 3개월, 40℃ 및 25℃에 4개월, 5℃에 5개월 보관하였다. 모든 바이알은 충전 직후에 이물이 없이 깨끗한 성상이었으며, 삼투압이 284-306 mOsm/kg, 전기전도도는 2.79-3.87 mS/cm 이었다. After adding sodium hydroxide to 1.07 mg/mL and deoxycholic acid (DCA, obtained from Sigma-aldrich) to 10 mg/mL to 80-85 ml of water for injection at about 25-30° C., at 300 rpm Stir for about 20 minutes to fully dissolve. Sodium phosphate monobasic (sodium phosphate monobasic), sodium citrate (sodium citrate), glycerol (glycerol), sucrose (sucrose) to the obtained solution was added to the concentration according to the following Table 6 and further stirred to dissolve all. Then, if necessary, 1N sodium hydroxide was added in small portions to adjust the pH as shown in Table 6 below, and then adjusted to a final volume of 100 ml with water for injection. After sterilization and filtration with a membrane filter (PES 0.22μm filter, Millipore, USA), the vials were filled and stored at 55°C for 3 months, at 40°C and 25°C for 4 months, and at 5°C for 5 months. All vials were clean without foreign matter immediately after filling, and the osmotic pressure was 284-306 mOsm/kg and the electrical conductivity was 2.79-3.87 mS/cm.
각 온도에 정해진 보관 기간 만큼 보관 후 바이알을 불출하여 이물 검사를 실시하였다. 55℃ 3개월, 40℃ 4개월, 25℃ 4개월, 5℃ 5개월 보관 후 실시예 23-34의 모든 바이알에서 이물 또는 겔화가 발생하지 않았다. 이로써 실시예 23-34의 모든 구성이 DCA를 안정하게 유지하는 조성임을 확인하였다. After storage for the specified storage period at each temperature, the vial was discharged and inspected for foreign substances. After storage at 55°C for 3 months, at 40°C for 4 months, at 25°C for 4 months, and at 5°C for 5 months, no foreign matter or gelation occurred in any of the vials of Examples 23-34. As a result, it was confirmed that all the compositions of Examples 23-34 were compositions for stably maintaining DCA.
실시예 35-38Examples 35-38
DCA의 액상제형 별 저온 노출 후 겔화 여부 및 겔화 후 겔이 액상으로 돌아오는데 걸리는 시간을 아래와 같이 평가하였다. 약 20-30℃의 주사용수 70-90 ml에 최종 농도 기준 수산화나트륨을 1.07mg/mL, 데옥시콜린산(DCA, Sigma-aldrich사로부터 입수)을 10mg/mL가 되도록 첨가한 후 교반하여 충분히 용해시켰다. 얻어진 용액에 소듐 포스페이트 모노베이직(sodium phosphate monobasic) 및/또는 소듐 시트레이트(sodium citrate)를 아래 표 7에 따른 농도로 첨가하여 4종의 제형을 실시예 35-38의 기본 제형으로 구성하였다. 상기 기본 제형 실시예 35-38의 구성에 폴리올(polyol) 미첨가, 만니톨(mannitol) 25mM, 50mM, 250mM, 및 500mM, 수크로오스(sucrose) 25mM, 50mM, 250mM, 500mM, 글리세롤(glycerol) 25mM, 50mM, 250mM, 500mM이 되도록 추가 폴리올을 첨가 및 추가 교반하여 모두 용해시켰다. 필요시 1N HCl 또는 1N NaOH를 소량씩 가하여 pH가 7.5가 되도록 조절하고 주사용수로 최종 부피 100ml을 맞추어 총 52종의 제형을 제조하였다. 이를 각각 멤브레인 필터(PES 0.22μm 필터, Millipore, USA)로 제균 여과한 후 바이알에 2mL씩 충진하고 5℃에 23일 보관하였다. For each liquid formulation of DCA, the gelation after low temperature exposure and the time it takes for the gel to return to the liquid phase after gelation were evaluated as follows. After adding sodium hydroxide to a final concentration of 1.07 mg/mL and deoxycholic acid (DCA, obtained from Sigma-aldrich) to 10 mg/mL to 70-90 ml of water for injection at about 20-30° C. dissolved. Sodium phosphate monobasic and/or sodium citrate were added to the obtained solution at concentrations according to Table 7 below, and four types of formulations were constituted as basic formulations of Examples 35-38. No polyol added to the composition of the basic formulation Examples 35-38, mannitol 25mM, 50mM, 250mM, and 500mM, sucrose 25mM, 50mM, 250mM, 500mM, glycerol 25mM, 50mM , 250 mM and 500 mM of additional polyol were added and further stirred to dissolve all of them. If necessary, 1N HCl or 1N NaOH was added in small portions to adjust the pH to 7.5, and the final volume was adjusted to 100ml with water for injection to prepare a total of 52 formulations. Each of these was filtered through a membrane filter (PES 0.22 μm filter, Millipore, USA), 2 mL each was filled in a vial, and stored at 5°C for 23 days.
5℃에 3일 보관 후, 23일 보관 후, 상온 불출 후 15분, 30분, 45분, 60분, 90분 시점에 겔화 유무를 확인하였고, 상온 불출 후 90분 시점에 이물 발생여부를 확인하였다. 3일 및 23일 보관 후 겔화 유무 관찰시에는 상온 노출에 의한 영향이 없도록 콜드룸 내에서 겔화 여부를 확인하였다. After storage at 5°C for 3 days and storage for 23 days, gelation was checked at 15 minutes, 30 minutes, 45 minutes, 60 minutes, and 90 minutes after dispensing at room temperature, and foreign matter was checked at 90 minutes after dispensing at room temperature. did. After storage for 3 days and 23 days, when observing the presence of gelation, it was checked whether or not gelation occurred in a cold room so that there was no effect by exposure to room temperature.
실시예 35-38의 모든 제형은 5℃ 3일 보관후 겔이 발생하지 않았다. 이에 따라 모든 제형은 5℃에서 3일까지 안정한 것으로 확인되었다. All formulations of Examples 35-38 did not develop a gel after storage at 5° C. for 3 days. Accordingly, all formulations were confirmed to be stable at 5°C for up to 3 days.
소듐 포스페이트 및 소듐 시트레이트를 모두 포함하지 않은 실시예 35 그룹 제형들은 5℃에 23일 까지 보관 하더라도 겔이 발생되지 않았다. 실시예 36, 37, 38 그룹의 제형들은 5℃, 3일까지는 겔이 발생하지 않았으나, 23일 보관후에는 겔이 발생하는 것이 확인되었다. 이들 제형을 상온 불출후 15분, 30분, 45분, 60분, 90분 시점에 겔 유무를 확인하였으며, 겔이 사라진 시점(불출후 시간, 분)을 아래 표 8에 나타내었다. The formulations of the Example 35 group containing neither sodium phosphate nor sodium citrate did not form a gel even if stored at 5° C. for up to 23 days. The formulations of Examples 36, 37, and 38 groups did not generate a gel at 5° C. until 3 days, but it was confirmed that gels were generated after storage for 23 days. After dispensing these formulations at room temperature, the presence of gel was checked at 15, 30, 45, 60, and 90 minutes, and the time point at which the gel disappeared (time, minutes after dispensing) is shown in Table 8 below.
Sodium Citrate 5mMSodium Phosphate monobasic 5 mM,
Sodium Citrate 5mM
*: 시간이 0인 경우 5℃ 보관 23일 후 겔(gel)이 발생하지 않음. *: When the time is 0, no gel is generated after 23 days of storage at 5°C.
실시예 36의 그룹의 경우 수크로오스 500mM를 포함한 제형은 5℃ 23일 보관 후에도 겔이 발생하지 않았다. 수크로오스 250mM을 포함한 제형은 상온 불출 15분 후, 그 외의 제형은 모두 30분 후 겔이 없어지며, 겔이 없음을 확인하였고, 이물 검사 결과 모든 바이알에 이물이 확인되지 않았다. 따라서 실시예 36의 그룹의 모든 제형은 저온에서 겔이 발생하더라도 상온에서 30분 정도 방치할 경우 액상이 되며 환자에게 주사할 수 있음을 확인하였다. 또한 수크로오스를 500mM 포함한 제형의 경우 겔 생성 방지 효과가 있으며, 수크로오스를 250mM 포함한 경우 저온에서 발생한 겔이 액상으로 돌아오는데 걸리는 시간이 짧아지는 효과가 있어 사용 편의성이 높음을 확인하였다. In the case of the group of Example 36, the formulation containing 500 mM sucrose did not form a gel even after storage at 5° C. for 23 days. For formulations containing 250 mM sucrose, the gel disappeared after 15 minutes of dispensing at room temperature, and all other formulations after 30 minutes, and it was confirmed that there was no gel. Therefore, it was confirmed that all formulations of the group of Example 36 became liquid when left at room temperature for about 30 minutes, even if gels were generated at low temperatures, and could be injected into patients. In addition, the formulation containing 500 mM sucrose has an effect of preventing gel formation, and when containing 250 mM sucrose, it has the effect of shortening the time it takes for the gel generated at low temperature to return to the liquid phase, thereby confirming high ease of use.
실시예 37 그룹의 경우 폴리올을 포함한 모든 조성이 폴리올이 없는 조성보다 액상이 되는데 걸린 시간이 짧았다. 폴리올을 포함한 제형은 45분 이내에, 폴리올을 포함하지 않은 제형은 90분 이후 겔이 발견되지 않았으며, 모든 바이알내에서 이물도 발견되지 않았다. 이에 따라 실시예 37의 모든 제형도 겔이 발생하더라도 상온 방치 90분 이후 액상이 되며, 환자에게 주사가능함을 확인하였다. 또한 만니톨, 수크로오스 또는 글리세롤 등의 폴리올이 포함된 경우 저온 보관시 겔이 발생하더라도 상온 방치시 더욱 빠르게 액상으로 변하기 때문에 폴리올을 포함한 제형이 사용 편의성이 높음을 확인하였다. In the case of the Example 37 group, the time taken for all compositions including polyols to become liquid was shorter than those without polyols. No gel was found in the formulation containing the polyol within 45 minutes and the formulation without the polyol after 90 minutes, and no foreign matter was found in any of the vials. Accordingly, it was confirmed that all formulations of Example 37 became liquid after 90 minutes left at room temperature even if gels were generated, and that they were injectable to the patient. In addition, when polyols such as mannitol, sucrose, or glycerol are included, it was confirmed that the formulation containing the polyol is more convenient to use because it changes to a liquid more quickly when left at room temperature even if a gel is generated when stored at a low temperature.
실시예 38 그룹의 경우 수크로오스 또는 글리세롤을 50mM, 250mM 또는 500mM 포함한 제형이 그 외의 제형보다 상온 방치시 액상으로 돌아오는데 걸리는 시간이 더 짧았고, 그 외의 시료의 경우에는 상온 보관 90분 후 모두 액상이었다. 이에 따라 실시예 38의 모든 제형도 겔이 발생하더라도 상온 방치 90분 이후 모두 액상이며, 환자에게 주사가능함을 확인하였다. 또한 적절한 폴리올을 포함한 경우 저온에서 생성된 겔이 상온에서 더욱 빨리 액상이 되기 때문에 폴리올을 사용한 제형이 사용 편의성이 더욱 높음을 확인하였다. In the case of Example 38 group, the formulation containing 50 mM, 250 mM or 500 mM sucrose or glycerol took a shorter time to return to liquid when left at room temperature than the other formulations, and in the case of other samples, they were all liquid after 90 minutes of storage at room temperature. Accordingly, it was confirmed that all formulations of Example 38 were liquid after 90 minutes left at room temperature even if gels were generated, and that they were injectable to the patient. In addition, when an appropriate polyol is included, it was confirmed that the formulation using the polyol is more convenient to use because the gel produced at low temperature becomes liquid more quickly at room temperature.
실시예 39-44Examples 39-44
데옥시콜린산(DCA) 액상 제형에 대한 금속이온의 영향을 평가하기 위하여 DCA 10mg/mL, 수산화나트륨 1.07 mg/mL, pH 7.8, HCl 적량의 용액을 제조하였다. 제조 방법은 최종 pH를 7.8로 맞추는 것 외에는 실시예 35 중에서 폴리올 미포함 제형의 제조방법과 동일하게 제조하였다. 제조된 용액에 염화철(Iron Chloride)를 철(iron) 농도 10ppm이 되도록 첨가하여 육안 관찰 결과 이물이 발생하였고, 이에 따라 금속 이온이 데옥시콜린산(DCA) 침전을 유발할 수 있음을 확인하였다. 금속이온은 생산 공정에서 사용되는 설비의 스테인레스 스틸, 부형제의 불순물, 포장용기 등으로부터 유래할 수 있다. To evaluate the effect of metal ions on deoxycholic acid (DCA) liquid formulation, an appropriate amount of DCA 10 mg/mL, sodium hydroxide 1.07 mg/mL, pH 7.8, and HCl was prepared. The preparation method was the same as the preparation method of the polyol-free formulation in Example 35, except that the final pH was adjusted to 7.8. Iron Chloride was added to the prepared solution so as to have an iron concentration of 10 ppm, and as a result of visual observation, foreign substances were generated, and it was confirmed that metal ions could cause deoxycholic acid (DCA) precipitation. Metal ions may come from stainless steel of equipment used in the production process, impurities in excipients, packaging containers, etc.
소듐 시트레이트(sodium citrate)가 데옥시콜린산 액상 제형의 금속이온에 대한 안정성을 향상시키는지 확인하기 위하여 아래와 같이 제형 제조 및 안정성 시험을 진행하였다. 실시예 39-44의 조성을 실시예 35-38의 조성과 유사한 방법으로 제조하였다. 제조한 조성을 SUS316L로 제조된 용기에 상온에서 6일 보관 후, PES 재질의 멤브레인 필터를 이용하여 여과한 후, 바이알에 2mL씩 충전하여 55℃ 안정성 챔버에 16일 동안 보관한 후, 육안 관찰하여 이물 생성 정도를 비교하였다. 소듐 시트레이트가 포함된 실시예 40 및 42 조성의 경우 동일 조성이면서 소듐 시트레이트가 포함되지 않은 실시예 39 및 41에 비해 이물 생성 정도가 현저히 줄어든 것을 확인하였고, 이에 따라 소듐 시트레이트가 데옥시콜린산(DCA) 제형의 안정성에 기여함을 확인할 수 있었다. 또한, 실시예 41 및 43의 조성을 실시예 39 조성과 비교하면, 포스페이트와 글리세롤도 데옥시콜린산 제형의 안정성에 기여함을 확인하였다. In order to confirm whether sodium citrate improves the stability of the deoxycholic acid liquid formulation against metal ions, formulation preparation and stability tests were carried out as follows. The composition of Examples 39-44 was prepared in a manner similar to the composition of Examples 35-38. After storing the prepared composition in a container made of SUS316L at room temperature for 6 days, filtering it using a membrane filter made of PES material, filling each vial by 2mL and storing it in a stability chamber at 55℃ for 16 days, visually observing foreign substances The degree of production was compared. In the case of the compositions of Examples 40 and 42 containing sodium citrate, it was confirmed that the degree of foreign material formation was significantly reduced compared to Examples 39 and 41 which had the same composition but did not contain sodium citrate, and accordingly, sodium citrate was deoxycholine It was confirmed that the acid (DCA) contributes to the stability of the formulation. In addition, when the composition of Examples 41 and 43 was compared with the composition of Example 39, it was confirmed that phosphate and glycerol also contributed to the stability of the deoxycholic acid formulation.
이물 생성 정도*55℃ after 16d
Degree of foreign body generation*
* 0: 훈련된 작업자가 육안으로 확인할 수 있는 침전 없음* 0: No sedimentation visible to the naked eye by trained operators
1: 훈련된 작업자가 육안으로 확인할 수 있는 침전 있음 1: Has deposits visible to the naked eye by trained operators
2: 훈련되지 않은 작업자가 육안으로 수초 내로 확인할 수 있는 수준의 침전 있음 2: There is a level of sedimentation visible to the naked eye within seconds by an untrained operator
3: 훈련되지 않은 작업자가 육안으로 바로 확인할 수 있는 수준의 침전 있음. 3: There is a level of sedimentation that is immediately visible to the naked eye by an untrained operator.
Claims (16)
약제학적으로 허용 가능한 첨가제를 포함하며,
pH가 7.0 내지 8.0이고,
25℃에서 전기전도도가 5mS/cm 이하인 약제학적 조성물.
Including deoxycholic acid (DCA) or a pharmaceutically acceptable salt thereof,
Contains pharmaceutically acceptable excipients,
a pH of 7.0 to 8.0;
A pharmaceutical composition having an electrical conductivity of 5 mS/cm or less at 25°C.
상기 첨가제는 폴리올(polyol), 아미노산(amino acid) 및 비이온성 계면활성제(non-ionic surfactant)로 이루어진 군에서 선택된 적어도 하나 이상을 포함하는 약제학적 조성물.
According to claim 1,
The additive is a pharmaceutical composition comprising at least one selected from the group consisting of polyols, amino acids, and non-ionic surfactants.
상기 폴리올은 수크로오스(sucrose), 글리세롤(glycerol), 만니톨(mannitol), 소르비톨(sorbitol), 프로필렌글리콜(propylene glycol), 트레할로스(trehalose), 에틸렌글리콜(ethyleneglycol), 말토스(maltose), 글루코스(glucose) 및 폴리에틸렌글리콜(polyethyleneglycol)으로 이루어진 군에서 선택된 적어도 하나 이상인 약제학적 조성물.
3. The method of claim 2,
The polyol is sucrose, glycerol, mannitol, sorbitol, propylene glycol, trehalose, ethylene glycol, maltose, glucose ) and at least one pharmaceutical composition selected from the group consisting of polyethylene glycol (polyethyleneglycol).
상기 아미노산은 히스티딘(histidine), 메티오닌(methionine), 글리신(glycine), 알라닌(alanine), 발린(valine), 류신(leucine), 이소류신(isoleucine), 티로신(tyrosine), 프롤린(proline), 페닐알라닌(phenylalanine), 아스파라진(asparagine), 글루타민(glutamine), 세린(serine), 트레오닌(threonine), 시스테인(cysteine) 및 트립토판(tryptophane)으로 이루어진 군에서 선택된 적어도 하나 이상인 약제학적 조성물.
3. The method of claim 2,
The amino acids are histidine, methionine, glycine, alanine, valine, leucine, isoleucine, tyrosine, proline, phenylalanine ( At least one pharmaceutical composition selected from the group consisting of phenylalanine, asparagine, glutamine, serine, threonine, cysteine and tryptophane.
상기 비이온성 계면활성제는 폴록사머(poloxamer) 및 폴리소르베이트(polysorbate)로 이루어진 군에서 선택된 적어도 하나 이상인 약제학적 조성물.
3. The method of claim 2,
The nonionic surfactant is at least one pharmaceutical composition selected from the group consisting of poloxamer and polysorbate.
상기 첨가제를 0.1 내지 500mM으로 포함하는 약제학적 조성물.
3. The method of claim 2,
A pharmaceutical composition comprising the additive in an amount of 0.1 to 500 mM.
상기 데옥시콜린산(Deoxycholic acid, DCA) 또는 그의 약제학적으로 허용되는 염을 1 내지 50mg/mL으로 포함하는 약제학적 조성물.
According to claim 1,
A pharmaceutical composition comprising the deoxycholic acid (DCA) or a pharmaceutically acceptable salt thereof in an amount of 1 to 50 mg/mL.
상기 약제학적 조성물은 pH 조절제 또는 pH 완충제(buffer)를 더 포함하는 것인, 약제학적 조성물.
3. The method of claim 2,
The pharmaceutical composition further comprises a pH adjusting agent or a pH buffer (buffer), the pharmaceutical composition.
상기 pH 조절제 또는 pH 완충제(buffer)는 시트르산나트륨, 수산화나트륨, 아디프산, 시트르산, 인산, 소듐포스페이트, 디소듐포스페이트, 모노나트륨인산염, 무수인산수소나트륨, 탄산칼슘, 수산화칼슘, 젖산칼슘, 말레산, 말산, 글루탐산나트륨, 아세트산나트륨, 탄산수소나트륨, 시트르산삼나트륨, 소듐락테이트, 및 트리에탄올아민으로 이루어지는 군에서 선택되는 적어도 하나 이상인 약제학적 조성물.
9. The method of claim 8,
The pH adjusting agent or pH buffer is sodium citrate, sodium hydroxide, adipic acid, citric acid, phosphoric acid, sodium phosphate, disodium phosphate, monosodium phosphate, anhydrous sodium hydrogen phosphate, calcium carbonate, calcium hydroxide, calcium lactate, maleic acid , malic acid, sodium glutamate, sodium acetate, sodium hydrogen carbonate, trisodium citrate, sodium lactate, and at least one pharmaceutical composition selected from the group consisting of triethanolamine.
상기 pH 조절제 또는 pH 완충제(buffer)를 0.1 내지 30 mM의 농도로 포함하는 약제학적 조성물.
9. The method of claim 8,
A pharmaceutical composition comprising the pH adjusting agent or pH buffer at a concentration of 0.1 to 30 mM.
상기 약제학적 조성물은 벤질알코올을 포함하지 않는 약제학적 조성물.
According to claim 1,
The pharmaceutical composition is a pharmaceutical composition that does not contain benzyl alcohol.
상기 약제학적 조성물은 염화 벤잘코늄, 염화 벤잘토늄, 페놀, 크레졸, 클로로크레솔 및 클로로부탄올을 포함하지 않는 약제학적 조성물.
According to claim 1,
The pharmaceutical composition does not contain benzalkonium chloride, benzaltonium chloride, phenol, cresol, chlorocresol and chlorobutanol.
수성 비경구 투여용 제제로 제제화되는 것인 약제학적 조성물.
According to claim 1,
A pharmaceutical composition that is formulated as an aqueous formulation for parenteral administration.
피하 주사용 제제인 약제학적 조성물.
According to claim 1,
A pharmaceutical composition for subcutaneous injection.
지방을 분해하는데 사용되는 것인 약제학적 조성물.
According to claim 1,
A pharmaceutical composition for use in breaking down fat.
비만의 예방 또는 치료를 위한 것인 약제학적 조성물. According to claim 1,
A pharmaceutical composition for the prevention or treatment of obesity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020230143813A KR20230152636A (en) | 2020-02-26 | 2023-10-25 | Pharmaceutical composition comprising deoxycholic acid |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200023930 | 2020-02-26 | ||
| KR20200023930 | 2020-02-26 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020230143813A Division KR20230152636A (en) | 2020-02-26 | 2023-10-25 | Pharmaceutical composition comprising deoxycholic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210108902A true KR20210108902A (en) | 2021-09-03 |
| KR102598758B1 KR102598758B1 (en) | 2023-11-07 |
Family
ID=77490128
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210025503A KR102598758B1 (en) | 2020-02-26 | 2021-02-25 | Pharmaceutical composition comprising deoxycholic acid |
| KR1020230143813A KR20230152636A (en) | 2020-02-26 | 2023-10-25 | Pharmaceutical composition comprising deoxycholic acid |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020230143813A KR20230152636A (en) | 2020-02-26 | 2023-10-25 | Pharmaceutical composition comprising deoxycholic acid |
Country Status (3)
| Country | Link |
|---|---|
| KR (2) | KR102598758B1 (en) |
| TW (1) | TWI768732B (en) |
| WO (1) | WO2021172897A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070110351A (en) * | 2005-02-08 | 2007-11-16 | 로스 엔젤레스 바이오메디칼 리서치 인스티튜트 엣 하버-유씨엘에이 메디칼 센터 | Methods and related compositions for reduction of fat and skin tightening |
| KR20190117318A (en) * | 2018-04-06 | 2019-10-16 | 다이나세라퓨틱스 주식회사 | Injection composition containing deoxycholic acid having excellent stability and method for preparing the same |
| KR20190120712A (en) | 2018-04-16 | 2019-10-24 | 주식회사 펜믹스 | Pharmaceutical composition containing deoxycholic acid |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8653058B2 (en) * | 2011-04-05 | 2014-02-18 | Kythera Biopharmaceuticals, Inc. | Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits |
| JP6219430B2 (en) * | 2016-03-18 | 2017-10-25 | キテラ バイオファーマシューティカルズ，インコーポレイテッド | Formulation of deoxycholic acid and its salts |
| KR102093872B1 (en) * | 2017-07-03 | 2020-03-27 | 진호성 | Injection Composition For Fat Reduction and method of manufacturing the same |
| KR102064864B1 (en) * | 2019-02-08 | 2020-01-10 | (주)제테마 | Topical injectable composition |
-
2021
- 2021-02-25 TW TW110106732A patent/TWI768732B/en active
- 2021-02-25 KR KR1020210025503A patent/KR102598758B1/en active IP Right Grant
- 2021-02-25 WO PCT/KR2021/002386 patent/WO2021172897A1/en active Application Filing
-
2023
- 2023-10-25 KR KR1020230143813A patent/KR20230152636A/en not_active Application Discontinuation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070110351A (en) * | 2005-02-08 | 2007-11-16 | 로스 엔젤레스 바이오메디칼 리서치 인스티튜트 엣 하버-유씨엘에이 메디칼 센터 | Methods and related compositions for reduction of fat and skin tightening |
| KR20190117318A (en) * | 2018-04-06 | 2019-10-16 | 다이나세라퓨틱스 주식회사 | Injection composition containing deoxycholic acid having excellent stability and method for preparing the same |
| KR20190120712A (en) | 2018-04-16 | 2019-10-24 | 주식회사 펜믹스 | Pharmaceutical composition containing deoxycholic acid |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102598758B1 (en) | 2023-11-07 |
| WO2021172897A1 (en) | 2021-09-02 |
| TW202140032A (en) | 2021-11-01 |
| KR20230152636A (en) | 2023-11-03 |
| TWI768732B (en) | 2022-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11179404B2 (en) | Formulations of deoxycholic acid and salts thereof | |
| US6548079B1 (en) | Moxifloxacin formulation containing common salt | |
| JP7042531B2 (en) | Pharmaceutical composition containing deoxycholic acid | |
| US20220072011A1 (en) | Treatments of accumulated fat with deoxycholic acid and salts thereof | |
| KR102034606B1 (en) | Formulations of deoxycholic acid and salts thereof | |
| EP2446878A1 (en) | Ketorolac tromethamine compositions for treating or preventing ocular pain | |
| KR101587056B1 (en) | Pharmaceutical compositios containing a fluoroquinolone antibiotic drug | |
| EP2561876B1 (en) | Formulations of Deoxycholic Acid and Salts Thereof | |
| EP2919755B1 (en) | Aqueous liquid composition containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid | |
| KR102598758B1 (en) | Pharmaceutical composition comprising deoxycholic acid | |
| KR101723703B1 (en) | Ketorolac tromethamine compositions for treating or preventing ocular pain | |
| EP2749266B1 (en) | Stable injectable pharmaceutical composition of vitamin D receptor agonist and process for preparation thereof | |
| EP3441073B1 (en) | Medicinal composition comprising fulvestrant | |
| KR100738021B1 (en) | Injectable formulation containing ginkgo biloba extracts in high concentration | |
| CN117279634A (en) | Pharmaceutical composition comprising compound SMTP-7 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| A107 | Divisional application of patent | ||
| GRNT | Written decision to grant |